Health and Personal Care Retailers (U.S.) — NAICS 456

A Histometrics rollup primer for both public-market and private investors. NAICS = North American Industry Classification System, the U.S. government's standard scheme for sorting businesses by their primary activity. This page covers the three-digit subsector 456. Because 456 contains only one child — industry group 4561 — this level is effectively identical to that child. This is a short bridge page: it gives the subsector's own ground-truth figures and points you to the full 4561 primer for the detail.

---

1. Overview

NAICS 456 is the store-based "health, wellness, and grooming" aisle of American retail — the specialty stores (physical and online) where consumers buy the goods that keep them medicated, well, good-looking, and able to see. It is one of retail's most defensive corners, because so much of what it sells is non-negotiable: a prescription refill, a hearing aid, a pair of eyeglasses.

The single most important structural fact about this subsector is that it has exactly one child, and so it is that child. Everything the federal classification files under 456 is also filed under 4561. There is no additional business hiding at the three-digit level — the numbers on this page and the numbers on the 4561 page are the same numbers. We therefore keep this page short and send you to the 4561 primer for the full treatment [1][2].

Acronyms are defined on first use. Company names, tickers, and financials are reserved to Sections 4 and 10, per house style.

---

2. What's inside — and why the subsector equals its one child

The three-digit subsector 456 contains a single four-digit child, 4561 (Health and Personal Care Retailers). A one-to-one parent and child means the rollup adds nothing the child does not already contain: same receipts, same firms, same concentration.

Where the real internal variety lives is one level further down, inside 4561, which splits into four very different five-digit industries:

• 45611 — Pharmacies and Drug Retailers: the CVS/Walgreens/independent-drugstore world, and by far the giant of the group (~83% of the level's sales) [2].
• 45612 — Cosmetics, Beauty Supplies, and Perfume Retailers: Ulta, Sephora, Sally, and thousands of neighborhood beauty-supply shops [2].
• 45613 — Optical Goods Retailers: LensCrafters, America's Best, Warby Parker, and the independent optician [2].
• 45619 — Other Health and Personal Care Retailers: vitamin/supplement shops plus hearing-aid centers and home-medical-equipment dealers [2].

So the useful mental model is: 456 → 4561 (identical) → four distinct businesses. All of the interesting contrast — pharmacy dominance, a growing beauty segment, a private/foreign-owned optical and "other" tier — is a 4561 story, told in full on that page. This page's job is only to establish that the subsector is a pass-through and to record its ground-truth totals [1][2].

---

3. Size (this level's rollup figures)

Our ground-truth federal statistics for NAICS 456 come from the 2022 Economic Census concentration file [1]. That file gives receipts, firm count, and concentration ratios — but not establishment counts, employment, or payroll. Because 456 equals 4561, these figures are identical to the 4561 primer's; the establishment, employment, and payroll lines are summed from the four grandchild primers (County Business Patterns 2023) and flagged as such.

How to read the concentration. The HHI (a standard gauge that squares and sums every firm's market share; 10,000 = pure monopoly, and U.S. antitrust convention calls anything under 1,500 "unconcentrated") comes out at 1,186.7 — technically unconcentrated. Yet the top four firms take 59% of all receipts, and those four are essentially the top four drug chains. The honest reading: a handful of pharmacy giants sits atop a fragmented long tail of nearly 50,000 firms — beauty-supply shops, opticians, vitamin stores, and hearing/medical-supply dealers. The full decomposition of why the number reads this way is in the 4561 primer [1][2].

Undercount caveat — large, and it runs the same direction throughout. The $654.6 billion is a specialty-storefront register, not the size of the underlying consumer economy for these goods. Prescriptions filled at Walmart, Costco, and Kroger; beauty bought at Target, Amazon, and department-store counters; optical departments inside warehouse clubs; and supplements sold at every mass channel are all booked under their host store's code, not here. And County Business Patterns counts only employer businesses, so the smallest solo operators — independent opticians, one-person medical-supply and hearing shops, tiny vitamin stores — fall below the line; this nonemployer undercount is most material in the optical and "other" fragments where individual ownership dominates. Treat $654.6 billion as roughly the brick-and-mortar specialty slice, materially smaller than what Americans actually spend on medicines, beauty, eyewear, supplements, and home-medical goods across all channels [2].

---

4. Investable universe (where value concentrates)

Because 456 equals 4561, there is no separate subsector-level investment picture — the investable universe is the 4561 universe. The one defining fact worth carrying up to this level: there is no single fund or ticker that cleanly represents the subsector, and the biggest slice is the hardest to own directly.

• Beauty (45612) offers the cleanest listed pure-play in the whole group — the store itself, buyable directly.
• Pharmacy (45611) is ~83% of the dollars but mostly indirect — consolidation has stripped out listed pure-plays, leaving exposure diluted inside insurer-pharmacy-benefit-manager (PBM = the middleman that sets pharmacy pay) conglomerates and mass/grocery/online retailers.
• Optical (45613) and the "other" bin (45619) are reachable mainly abroad or through private markets — a global optical giant on a European exchange, foreign-listed hearing groups, and private-equity (PE) roll-ups.

There is no dedicated NAICS-456 exchange-traded fund (ETF) or index; broad retail/consumer-discretionary ETFs hold a few of these names heavily diluted among many. For the full company-by-company map — tickers, public pure-plays, foreign parents, and private/PE routes across all four grandchildren — see the 4561 primer, Section 4 [2].

---

5. How the money works

There is no distinct "subsector" economics — the money works exactly as it does in 4561, which runs on four genuinely different engines:

• Pharmacies — reimbursement retail: a pharmacy is reimbursed by a PBM or payer at a contracted rate plus a dispensing fee; profit per prescription = (reimbursement − drug cost) + fee, a line PBMs have squeezed for years. Generics (about nine of ten U.S. prescriptions) are the profit backbone [2].
• Beauty — spread plus loyalty: markup between wholesale and retail, amplified by traffic, private label, in-store services, and a huge loyalty program; the health signal is comparable ("same-store") sales [2].
• Optical — product plus services plus managed care: frames and lenses (high markups) alongside exams and fittings, layered with insurance contracts [2].
• Other — two engines under one code: high-margin cash supplement retail versus device-plus-reimbursement hearing/home-medical-equipment (HME) with a resupply annuity [2].

The common thread: setting aside pharmacy's unique reimbursement plumbing, this is service- or loyalty-anchored, recurring-aftermarket retail — not thin-margin fast-moving goods. Regulated-utility rate-base, real-estate FFO, and mining-cost frameworks do not apply anywhere here; this is retail-plus-service economics. Full unit-economics detail is in the 4561 primer, Section 5 [2].

---

6. Demand drivers

The subsector's resilience comes from 4561's four children answering to largely independent demand systems, so a shock to one barely touches the others.

• Pharmacies: an aging, increasingly chronically ill population lifts prescription volume; the GLP-1 (glucagon-like peptide-1) obesity/diabetes-drug boom is a large volume tailwind [2].
• Beauty: product newness, social-media discovery (especially TikTok), and younger consumers treating beauty as wellness — relatively recession-resistant ("lipstick effect") but still discretionary [2].
• Optical: aging (near-universal presbyopia after the mid-40s), high sticky penetration, and rising screen-driven myopia [2].
• Other: broad habitual supplement use, plus a hearing/HME segment riding the demographic escalator — Americans 65-and-older reached 18% of the population in 2024 — and care moving into the home [2].

The unifying macro driver is demographics. Aging simultaneously lifts prescriptions, eyewear, hearing aids, and home-medical demand — three of the four children benefit directly, with beauty the one culturally-driven discretionary exception. That mix is what makes the subsector one of retail's more durable [2].

---

7. Regulation

This is one of the most heavily and variably regulated corners of retail — but, as with everything at this level, the regulatory picture is the 4561 picture, and the weight is wildly uneven across its four children:

• Pharmacies — the heaviest and most contested: state pharmacy boards, the Food and Drug Administration (FDA), the Drug Enforcement Administration (DEA), the Centers for Medicare & Medicaid Services (CMS), and health-privacy law, with PBM and competition policy the fastest-moving front (Federal Trade Commission (FTC) reports; phasing-in PBM reforms) [2].
• Beauty — light as retailing, tightening on product: the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) adds facility registration and safety duties that fall on private-label sellers [2].
• Optical — pro-competition retail rules on a medical-device base: the FTC Eyeglass and Contact Lens Rules require prescription release; the FDA regulates contact lenses as devices [2].
• Other — a split regime: supplements are lightly regulated as food, while hearing/HME faces a heavy device-and-reimbursement regime (the 2022 over-the-counter hearing-aid rule; CMS competitive bidding) [2].

The through-line: in the two health-heavy children (pharmacy, hearing/HME), reimbursement policy is the swing factor; in the two consumer-facing children (beauty, supplements), regulation is lighter and the risk is that it tightens. The full regulatory map is in the 4561 primer, Section 7 [2].

---

8. Consolidation

The subsector's consolidation story is the 4561 story: fragmented at the store level, consolidating at the ownership level — but toward different owners for different reasons in each child. Pharmacy has seen the most dramatic reshaping of U.S. retail pharmacy in a generation (a major chain liquidated, another taken private, nearly one in three retail pharmacies closed since 2010); beauty is a two-horse premium race; optical is shaped by vertically integrated giants and PE roll-ups; and hearing/HME is being remade by vertical integration of retailers with device makers.

The unifying dynamic: in every child, the winning consolidators pair stores with an upstream product engine (a PBM, a lens/device factory, a private-label line) or a payer network, capturing margin the standalone independent cannot. The recurring loser is the single-location, single-line independent squeezed between price-transparent online sellers and a vertically integrated giant that both supplies and competes with it. Deal-by-deal detail is in the 4561 primer, Section 8 [2].

---

9. Risks

Because 456 equals 4561, the risk set is identical. Shared across the subsector:

• Channel disintermediation — every child cedes volume to Amazon, Walmart, Costco, and direct/online sellers; the biggest competitive threat in each case sits outside the NAICS code.
• Vertical squeeze on the fragmented independent tail, which increasingly buys from firms that also own competing retail.
• Fixed-cost store networks losing leverage as sales shift online, plus shortages of licensed professionals (pharmacists, opticians, audiologists).
• Product safety, recall, and liability exposure that can land on the retailer even when manufacturing is outsourced.
• Private-company opacity and measurement risk — much of the level is private, PE-owned, or foreign-parent-owned, and federal data undercount nonemployers and route huge volumes to other codes, so headline figures understate the real markets.

Child-specific risks — pharmacy reimbursement compression and legacy liabilities, beauty's discretionary/theft/tariff exposure, optical's payer pressure and deferrable big-ticket sensitivity, and the "other" bin's supplement-tightening and hearing-reimbursement/foreign-listing risks — are detailed in the 4561 primer, Section 9 [2].

---

10. How to invest, and the outlook

The signature of this subsector for an investor is that it is really four businesses reachable through four different instruments — and the biggest one is the hardest to own directly. Since 456 equals 4561, the practical menu is the 4561 menu:

• Public-market routes are largely indirect. Beauty (45612) offers the cleanest listed pure-play; optical (45613) is reachable through a diversified global giant plus a U.S. pure-play and a direct-to-consumer (DTC) name; pharmacy (45611) — 83% of the dollars — runs mostly through insurer-PBMs and mass/grocery/online hosts; and the "other" bin (45619) is proxies only, most directly via foreign hearing groups and U.S. home-medical billers.
• Private-market routes are the direct exposure across three of the four children — an independent community pharmacy, a beauty-supply or optical store, a franchised hearing center, or a PE-backed roll-up. At the tail this is, genuinely, a small-business economy.

Outlook (forward-looking judgment; the federal data carry no forecast, so no growth rate is asserted). The subsector is best understood as four clocks running at different speeds: pharmacy volume grows with demographics while dispensing value concentrates in vertically integrated platforms and lower-cost channels; beauty sees steady low-single-digit growth with resilient physical stores; optical rests on a durable, slow-moving demographic base with value/DTC formats gaining; and the "other" bin runs two-speed, with supplement specialty stores ceding share online while hearing/HME stays demographically floored.

For most public investors the practical exposure is therefore a mosaic — a beauty pure-play, a pharmacy conglomerate, an optical giant, and a foreign hearing group — because no single instrument captures "health and personal care retail." That the largest slice (pharmacy) is nearly un-buyable as a pure play, while the smallest offers the cleanest ones, is the defining irony of this subsector.

➡️ For the full treatment — company-by-company tables, unit economics, the complete regulatory map, deal histories, diligence checklists, and the four grandchild leaf primers (45611, 45612, 45613, 45619) — see the NAICS 4561 primer, which this page is identical to at the aggregate level.

---

Sources

1. U.S. Census Bureau, 2022 Economic Census — Concentration of Largest Firms, NAICS 456 (our ground-truth file: receipts $654.6B; 49,659 firms; CR4 59.0% / CR8 64.6% / CR20 70.0% / CR50 74.1%; HHI 1,186.7). Identical to NAICS 4561 because 456 has a single child. https://data.census.gov/table/ECNSIZE2022.EC2200SIZECONCEN
2. Histometrics primer, NAICS 4561 — Health and Personal Care Retailers (the single child of 456; synthesizes the 2022 Economic Census, County Business Patterns 2023, and the four grandchild leaf primers for 45611 Pharmacies, 45612 Cosmetics/Beauty, 45613 Optical, and 45619 Other — with their IQVIA, Drug Channels, FTC, The Vision Council, CRN/Ipsos, CMS, and SEC-filing sources carried through).